Fujifilm Diosynth Biotechnologies, a biologics firm, has chosen Fluor to carry out procurement and building administration for a large-scale biologics drug substance manufacturing facility in Denmark, the contractor introduced Thursday.
The Irving, Texas-based firm will guide the multi-hundred-million-dollar reimbursable contract worth within the third quarter of 2022, in line with an organization launch.
The power will produce new capability for superior biologics utilized in a wide range of remedies together with vaccines, oncology and quality-of-life medicines. Fluor anticipates the ability to be operational by 2025, in line with the discharge.
However Fluor’s focus in massive tasks additionally poses dangers, stated Andrew Wittmann, senior analysis analyst at Milwaukee-based monetary providers firm Baird, in a analysis word shared with Building Dive in August. Massive mission awards drive a lot of Fluor’s enterprise, however that ends in “lumpier bookings and can lead to bigger mission fees, ought to mission execution deteriorate,” he stated.
The engineering and building agency each missed estimates and trimmed steerage in its most up-to-date earnings report in August. Nonetheless, CEO David Constable stated the corporate stays “on monitor to ship our expectations for 2022 and on our key strategic priorities for 2024.”
Fluor’s City Options section is main the mission with assist from its Nordic Know-how Hub in Copenhagen, Denmark.